Takeda Sees Portfolio As Mostly Pandemic-Resistant
But Some Trials Being Impacted
Takeda says the coronavirus is affecting some of its clinical programs but that many key pipeline assets remain on track, while its existing commercial portfolio is seen as resilient by nature.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.